Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Cancer Lett. 2020 Aug 1;484:1-8. doi: 10.1016/j.canlet.2020.04.008. Epub 2020 Apr 11.
Cancer Lett. 2020.
PMID: 32289441
Free article.